Study M317
Study name | Hellem TL 2015 |
Title | Creatine as a novel treatment for depression in females using methamphetamine: a pilot study |
Overall design | The purpose of this pilot study was to investigate creatine monohydrate as a treatment for depression in female methamphetamine users. Fourteen females with depression and comorbid methamphetamine dependence were enrolled in an 8-week open label trial of 5 g of daily creatine monohydrate and of these 14, 11 females completed the study. Depression was measured using the Hamilton Depression Rating Scale (HAMD) and brain phosphocreatine levels were measured using phosphorus magnetic resonance spectroscopy pre- and post-creatine treatment. There were a total of 10 scan completers. Secondary outcome measures included anxiety symptoms, measured with the Beck Anxiety Inventory (BAI), as well as methamphetamine use, monitored by twice weekly urine drug screens and self-reported use. For metabolite quantification, the peak area was normalized by the total phosphorous signal. |
Study Type | Type2; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression with comorbidity; Depression with comorbidity; |
Criteria for depression | DSM-IV diagnosed MDD, HAMD-17 >= 15 |
Sample size | 10 |
Tissue | Central; Brain; Frontal lobe; |
Platform | MRS; MRS: Siemens 3 T MRI scanner (Siemens AG, Munich, Germany); |
PMID | |
DOI | |
Citation | Hellem TL, Sung YH, Shi XF, et al. Creatine as a novel treatment for depression in females using methamphetamine: a pilot study. J Dual Diagn 2015;11(3-4):189-202. |
Metabolite |
